Improving Survival in Metastatic Urothelial Cancer

Improving Survival in Metastatic Urothelial Cancer

Episodes

Specialty:

All

Year:

All

EP. 1: Current Status of Therapy: Metastatic Urothelial Cancer

ByShilpa Gupta, MD, Cleveland Clinic,Jeanny Aragon-Ching, MD, Inova Schar Cancer Institute

August 26th 2020

EP. 2: PD-L1 Expression in Metastatic Urothelial Cancer

ByShilpa Gupta, MD, Cleveland Clinic,Jeanny Aragon-Ching, MD, Inova Schar Cancer Institute

August 26th 2020

EP. 3: Value of PD-L1 Testing in Metastatic Urothelial Cancer

ByShilpa Gupta, MD, Cleveland Clinic,Jeanny Aragon-Ching, MD, Inova Schar Cancer Institute

August 26th 2020

EP. 4: Switch Maintenance Strategy for Metastatic Bladder Cancer

ByShilpa Gupta, MD, Cleveland Clinic,Jeanny Aragon-Ching, MD, Inova Schar Cancer Institute

August 26th 2020

EP. 5: Increased Survival Outcomes with Switch Maintenance in mUC

ByShilpa Gupta, MD, Cleveland Clinic,Jeanny Aragon-Ching, MD, Inova Schar Cancer Institute

August 26th 2020

EP. 6: Safety Data from JAVELIN Bladder 100

ByShilpa Gupta, MD, Cleveland Clinic,Jeanny Aragon-Ching, MD, Inova Schar Cancer Institute

August 26th 2020

EP. 7: Practical Management of AEs in Metastatic Bladder Cancer

ByShilpa Gupta, MD, Cleveland Clinic,Jeanny Aragon-Ching, MD, Inova Schar Cancer Institute

August 26th 2020

EP. 8: Changing the Standard of Care in Metastatic Bladder Cancer

ByShilpa Gupta, MD, Cleveland Clinic,Jeanny Aragon-Ching, MD, Inova Schar Cancer Institute

August 26th 2020

EP. 9: Educating Patients on Maintenance Therapy in mUC

ByShilpa Gupta, MD, Cleveland Clinic,Jeanny Aragon-Ching, MD, Inova Schar Cancer Institute

August 26th 2020

EP. 10: Metastatic Bladder Cancer: Progression After Maintenance

ByShilpa Gupta, MD, Cleveland Clinic,Jeanny Aragon-Ching, MD, Inova Schar Cancer Institute

August 26th 2020

EP. 11: Sequencing Considerations in mUC after Frontline IO

ByShilpa Gupta, MD, Cleveland Clinic,Jeanny Aragon-Ching, MD, Inova Schar Cancer Institute

August 26th 2020

EP. 12: Bright Future in Advanced Urothelial Cancer

ByShilpa Gupta, MD, Cleveland Clinic,Jeanny Aragon-Ching, MD, Inova Schar Cancer Institute

August 26th 2020

Trending on OncLive

FDA Approves Lirafugratinib for Pretreated, Locally Advanced or Metastatic Cholangiocarcinoma

Dr Kahl on Frontline Strategies for Avoiding Autologous Transplant in MCL

Linvoseltamab Yields Deep, MRD-Negative Responses With Manageable Safety in High-Risk Smoldering Myeloma